Despite heterogeneity among animal models of alcoholism, it has been argued that pharmacological treatments evaluated in the clinical setting should also be assessed in the different animal models to test for pharmacological validity/generalizability (c.f., Litten et al., 2012). Therefore, it should be highlighted that naltrexone, and naloxone, consistently reduce ethanol intake in all of the lines in Table 4, as well as the UChB (Quintanilla and Tampier, 2000), FH/Wjd (Overstreet et al., 2007), and WHP (Dyr and Kostowski, 2008) rat lines. Results with acamprosate have been equivocal in Table 4, but are more promising in the FH/Wjd line (Overstreet et al., 2007). However, topiramate does reduce ethanol intake in P (Table 4) as well as HAD1 (KM Franklin, personal communication) rats but still needs to be tested in the other lines. Prazosin, an adrenergic α1 antagonist, consistently reduces ethanol in-take in P rats (Table 4) but needs to be tested in the other lines as well. Baclofen reduces ethanol self-administration under operant conditions in AA, P and sP rats (Table 4), although it has very modest effects in HAD1 and
